close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

41.80 +0.55 (+1.33%)
Delayed Quote Updated: 10:38 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
News headline image
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Golden Cross Appears Before Teva Pharmaceutical Indus Investors ↗
If history is any guide, there may be good fortune ahead for shares of Teva Pharmaceutical Indus (NYSE:TEVA). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
News headline image
Teva, Allergan Settle Opioid Lawsuit With West Virginia ↗
U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has reached an agreement with the Attorney General of West Virginia that settles the state's opioid-related claims. 
Via Benzinga
News headline image
Why Generic Drugs Giant Teva Pharmaceutical Just Cut Its 2022 Outlook ↗
Foreign exchange rates are weighing heavily on sales, according to the firm's CEO. 
Via Investor's Business Daily
News headline image
FDA Rejects Teva - MedinCell's Schizophrenia Candidate ↗
 
Via Benzinga
News headline image
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients ↗
 
Via Benzinga
News headline image
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal ↗
Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2022 ↗
 
Via Benzinga
News headline image
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
4 Analysts Have This to Say About Teva Pharmaceutical Indus ↗
Over the past 3 months, 4 analysts have published their opinion on Teva Pharmaceutical Indus (NYSE:TEVA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg ↗
 
Via Benzinga
News headline image
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Recap: Teva Pharmaceutical Q1 Earnings ↗
Teva Pharmaceutical Indus (NYSE:TEVA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Teva Reports First Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Earnings Scheduled For May 3, 2022 ↗
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
News headline image
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters ↗
 
Via Benzinga
News headline image
JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.